Merck & Co., Inc. (LON:0QAH)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 225.72B +23.3% |
| Revenue (ttm) | 48.30B +1.3% |
| Net Income | 13.56B +6.6% |
| EPS | 5.41 +8.0% |
| Shares Out | n/a |
| PE Ratio | 16.64 |
| Forward PE | 23.48 |
| Dividend | 2.47 (2.06%) |
| Ex-Dividend Date | Mar 16, 2026 |
| Volume | 8,423 |
| Average Volume | 90,298 |
| Open | 120.52 |
| Previous Close | 120.91 |
| Day's Range | 119.28 - 121.89 |
| 52-Week Range | 70.15 - 125.16 |
| Beta | 0.26 |
| RSI | 55.97 |
| Earnings Date | Apr 30, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial numbers in USD Financial StatementsNews
Swiss industry body says US tariffs on pharmaceuticals will harm patients
U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, supply chains and ultimately will harm patients, Switzerland's pharmaceutical association interph...
Drugmakers face 100% tariff unless they cut prices or produce drugs in US
The Trump administration said on Thursday it will impose 100% tariffs on branded pharmaceuticals imported into the United States unless manufacturers agree to government drug pricing deals or commit ...
Global pharma companies that have publicly announced Trump drug pricing agreements
U.S. President Donald Trump secured agreements with 16 major pharmaceutical companies to bring U.S. prescription drug prices in line with those paid in other developed nations in exchange for three-ye...
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of a pivotal Phase 2b/3 trial evaluating MK-8748 (also known as T...
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab), in combination with paclitaxel, with or ...
Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30.
Barclays names top 4 defensive stocks to weather global uncertainty
As Dow Jones slides into the “correction territory” and the benchmark S&P 500 index logs its fifth consecutive week of losses, investors are increasingly desperate for a port in the storm. According t...
Infinimmune, Merck enter into antibody discovery pact
Biotech firm Infinimmune said on Tuesday it has entered into a deal with Merck , that could be worth up to about $838 million in milestone payments, to discover and develop multiple antibodies for ...
Infinimmune Enters Collaboration with Merck to Discover Novel Human Antibody Therapeutics
ALAMEDA, Calif.--(BUSINESS WIRE)-- #AI--Infinimmune Enters Collaboration with Merck to Discover Novel Human Antibody Therapeutics.
Merck's drug reduced bad cholesterol by 64.6% in late-stage trial
Merck's oral drug reduced bad cholesterol by 64.6% in a late-stage trial, it said on Monday, as the company looks for its next blockbuster candidate.
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
RAHWAY, N.J.--(BUSINESS WIRE)--Enlicitide, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions Compared to Oral Non-Statin Therapies.
Merck & Co., Inc. (MRK) M&A Call Transcript
Merck & Co., Inc. (MRK) M&A Call Transcript
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst
The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.
Merck makes a big move into new cancer treatments with a $6.7 billion buyout deal
Merck to spend $6.7 billion to buy Terns Pharmaceuticals, which is developing an oral treatment for leukemia.
Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline
Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma
Merck said on Wednesday it would buy biotech Terns Pharma in a deal valued at up to $6.7 billion, as the drugmaker races to bolster its cancer pipeline ahead of the looming patent loss f...
Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns
The drugmaker has been seeking to bolster its pipeline as its top-selling drug, Keytruda, is set to lose patent protection.
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Terns' lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor c urrently in Phase 1/2 development for certain patients with CML
Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports
Merck is nearing a roughly $6 billion all-cash deal to buy biotech firm Terns Pharma , the Financial Times reported on Tuesday, citing people familiar with the matter.
Quotient Therapeutics Announces Collaboration with Merck to Discover Novel Drug Targets in Inflammatory Bowel Disease Using Somatic Genomics Platform Technology
CAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has entered a multi-year res...
FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), today announced the...
Merck Marks 10 Years of SPARK™ Mobilizing Employee Volunteers to Help Inspire the Next Generation in STEM
Darmstadt, Germany, March 18, 2026 (GLOBE NEWSWIRE) -- Employee volunteer program brings hands-on science learning to communities worldwide More than 600.000 students reached and nearly 200.000 employ...